{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T05:12:19Z","timestamp":1778303539214,"version":"3.51.4"},"reference-count":37,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Grants-in-Aid for Scientific Research","doi-asserted-by":"crossref","award":["23K06911"],"award-info":[{"award-number":["23K06911"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Grants-in-Aid for Scientific Research","doi-asserted-by":"crossref","award":["24K10535"],"award-info":[{"award-number":["24K10535"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Hereditary transthyretin amyloidosis (ATTRv), a multisystemic disorder caused by transthyretin (TTR) gene mutations, exhibits phenotypic heterogeneity that can hamper recognition in non-endemic areas. Here, we investigated the clinical practice of ATTRv amyloidosis over an extended period and examined the challenges currently faced in non-endemic regions. Materials and Methods: We conducted an observational study of 18 patients with ATTRv amyloidosis diagnosed at Oita University and its affiliated hospitals between 2000 and 2025, using both retrospective and prospective data collection, to evaluate clinical features, treatments, and outcomes. Results: The median age at disease onset was 64 years, and 27.8% of patients had a family history of the disease. Val30Met (V30M) was the most common (55.6%) mutation; Tyr114Ser was the most common non-V30M variant. Sensory disturbances (50%) were the most common initial symptoms, followed by cardiac symptoms (38.9%). The cardiology department most frequently diagnosed ATTRv amyloidosis, followed by the neurology department. Two patients were relatives of previously diagnosed probands and were therefore identified during their first visit to the initial department. New diagnoses increased over time (1 in 2000\u20132009, 7 in 2010\u20132019, and 10 in 2020\u20132025), although diagnostic delays persisted. After the therapeutic agents shifted from patisiran to vutrisiran, the serum TTR value decreased (p = 0.0078) without significant deterioration in cardiac parameters. In the current treatment era, longer-term survivors have been observed, but multiple organ dysfunction has become more apparent, and ocular manifestations have emerged as a clinically important problem, particularly in patients with longer disease duration (p = 0.0169). Conclusions: Physicians in various departments must remain vigilant for the presence of ATTRv amyloidosis. Addressing challenges faced by long-term survivors, including ocular manifestations and central nervous system complications, has become crucial, even in non-endemic areas.<\/jats:p>","DOI":"10.3390\/medicina62050907","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:07:16Z","timestamp":1778274436000},"page":"907","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Practice and Diagnostic Trends in Hereditary Transthyretin Amyloidosis: A 25-Year Observational Study"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2002-8870","authenticated-orcid":false,"given":"Kaori","family":"Sumi","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Oita University, Oita 879-5593, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-3339","authenticated-orcid":false,"given":"Teruaki","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Oita University, Oita 879-5593, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Oita 879-5593, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Oita 879-5593, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Aso","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oita Prefectural Hospital, Oita <sans-serif>870-851<\/sans-serif>, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Hazama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shin Beppu Hospital, Oita 874-8538, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konen","family":"Obayashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology, Graduate School of Life Sciences, Kumamoto University, Kumamoto 862-0976, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6814-0582","authenticated-orcid":false,"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9037-0010","authenticated-orcid":false,"given":"Naohiko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Oita 879-5593, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-7268","authenticated-orcid":false,"given":"Noriyuki","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Oita University, Oita 879-5593, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/13506129.2024.2405948","article-title":"Amyloid nomenclature 2024: Update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"31","author":"Buxbaum","year":"2024","journal-title":"Amyloid"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1474-4422(23)00334-4","article-title":"Hereditary transthyretin amyloid neuropathies: Advances in pathophysiology, biomarkers, and treatment","volume":"22","author":"Adams","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update","volume":"17","author":"Dispenzieri","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","article-title":"Transthyretin-related familial amyloidotic polyneuropathy","volume":"62","author":"Ando","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","article-title":"Natural history of transthyretin Val30Met familial amyloid polyneuropathy: Analysis of late-onset cases from non-endemic areas","volume":"83","author":"Koike","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Obici","year":"2016","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ana.26845","article-title":"Disease-modifying drugs extend survival in hereditary transthyretin amyloid polyneuropathy","volume":"95","author":"Ueda","year":"2024","journal-title":"Ann. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy","volume":"91","author":"Coelho","year":"2018","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.28026","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts","volume":"69","author":"Karam","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Rapezzi","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: A model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s13023-025-04006-6","article-title":"Genetic and clinical features of hereditary transthyretin amyloidosis: A decade of experience at a Japanese referral center","volume":"20","author":"Nomura","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","article-title":"A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"18","author":"Gentile","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1212\/WNL.0000000000005777","article-title":"Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy","volume":"91","author":"Lozeron","year":"2018","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ejhf.2658","article-title":"Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy","volume":"24","author":"Vela","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1212\/WNL.0000000000004016","article-title":"Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy","volume":"88","author":"Masuda","year":"2017","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/ene.15268","article-title":"Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis","volume":"29","author":"Leonardi","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_25","first-page":"497\u2013e36","article-title":"Upper limb onset of hereditary transthyretin amyloidosis is common in non-endemic areas","volume":"26","author":"Lozeron","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/13506120903094074","article-title":"The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy","volume":"16","author":"Koike","year":"2009","journal-title":"Amyloid"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s10741-021-10162-1","article-title":"Epidemiology and clinical manifestations of cardiac amyloidosis","volume":"27","author":"Bajwa","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cianci, V., Cianci, A., Sapienza, D., Crac\u00f2, A., German\u00e0, A., Ieni, A., Gualniera, P., Asmundo, A., and Mondello, C. (2024). Epidemiological changes in transthyretin cardiac amyloidosis: Evidence from in vivo data and autoptic series. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175140"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: Issues and challenges","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transpl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: After 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29","author":"Obici","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","article-title":"Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)","volume":"69","author":"Ferreira","year":"2007","journal-title":"Neurology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1161\/CIRCULATIONAHA.125.076330","article-title":"Efficacy of suppression of serum transthyretin with patisiran and vutrisiran in variant ATTR amyloidosis: An observational crossover study","volume":"153","author":"Razvi","year":"2026","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/13506129.2010.527068","article-title":"Transthyretin-related vitreous amyloidosis in different endemic areas","volume":"17","author":"Kawaji","year":"2010","journal-title":"Amyloid"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/archophthalmol.2009.390","article-title":"Impact of liver transplantation on transthyretin-related ocular amyloidosis in Japanese patients","volume":"128","author":"Hara","year":"2010","journal-title":"Arch. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/WNL.0000000000003001","article-title":"Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis","volume":"87","author":"Sekijima","year":"2016","journal-title":"Neurology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaneurol.2023.5762","article-title":"Origin of transthyretin in cerebral amyloid angiopathy","volume":"81","author":"Nomura","year":"2024","journal-title":"JAMA Neurol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/907\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:30:11Z","timestamp":1778301011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["medicina62050907"],"URL":"https:\/\/doi.org\/10.3390\/medicina62050907","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}